Comparing SG&A Expenses: Opthea Limited vs Rhythm Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: Opthea vs Rhythm Pharmaceuticals

__timestampOpthea LimitedRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 201426520411213000
Thursday, January 1, 201523615873425000
Friday, January 1, 201644728696311000
Sunday, January 1, 201750309579518000
Monday, January 1, 2018498894128080000
Tuesday, January 1, 2019519641236550000
Wednesday, January 1, 2020665277446125000
Friday, January 1, 20211841824768486000
Saturday, January 1, 20222482706692032000
Sunday, January 1, 202341896408117532000
Monday, January 1, 202415488619
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Opthea Limited and Rhythm Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Opthea's SG&A expenses surged by over 1,500%, peaking in 2023. In contrast, Rhythm Pharmaceuticals experienced a staggering increase of nearly 9,600% during the same period, highlighting its aggressive expansion strategy. Notably, Rhythm's expenses consistently outpaced Opthea's, reflecting its larger scale of operations. However, data for 2024 is incomplete, with Rhythm's figures missing, leaving room for speculation on future trends. This financial narrative underscores the dynamic nature of the pharmaceutical sector, where strategic spending can significantly impact a company's market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025